abstract
world
celebr
anniversari
discoveri
interferon
ifn
isaac
lindenmann
subsequ
gene
clone
fulli
sequenc
produc
recombin
form
recombin
use
basi
treatment
chronic
hepat
c
viru
infect
also
use
treat
certain
form
chronic
hepat
b
viru
infect
ifn
also
use
viral
infect
although
less
success
antivir
mechan
ifn
review
chapter
well
util
ifn
treatment
persist
viral
infect
caspas
recruit
domain
ds
doublestrand
erk
extracellular
signalregul
kinas
gaf
activ
factor
ga
activ
site
world
celebr
anniversari
discoveri
interferon
ifn
isaac
lindenmann
isaac
lindenmann
human
first
cytokin
purifi
homogen
subsequ
gene
clone
fulli
sequenc
produc
recombin
form
e
coli
nagata
et
al
recombin
use
basi
treatment
chronic
hepat
c
viru
hcv
infect
also
use
treat
certain
form
chronic
hepat
b
viru
hbv
infect
ifn
also
use
viral
infect
although
less
success
ifn
natur
glycoprotein
produc
cell
vertebr
respons
challeng
foreign
agent
infecti
organ
virus
bacteria
fungi
parasit
tumor
cell
ifn
produc
cell
innat
adapt
immun
system
nonimmun
cell
fibroblast
epitheli
cell
type
ifn
form
superfamili
innat
cytokin
compris
alpha
human
subtyp
beta
omega
tau
kappa
epsilon
lambda
zeta
pestka
et
al
express
human
subtyp
secret
leukocyt
wherea
also
produc
fibroblast
exclus
express
rumin
specif
stage
pregnanc
martal
et
al
wherea
express
human
keratinocyt
lafleur
et
al
human
type
ifn
gene
cluster
chromosom
intronless
encod
secretori
signal
peptid
sequenc
proteolyt
cleav
prior
secret
cell
type
ifn
genet
structur
close
relat
rang
length
amino
acid
appar
molecular
weight
kda
tabl
chen
et
al
differ
subtyp
human
approxim
amino
acid
sequenc
ident
wherea
share
approxim
amino
acid
ident
human
human
chen
et
al
one
known
type
ii
ifn
discov
wheelock
sibley
exclus
produc
immun
cell
activ
thymusderiv
cell
natur
killer
nk
cell
stimul
foreign
antigen
mitogen
earli
stage
innat
immun
respons
boehm
et
al
human
gene
map
chromosom
noncoval
ealick
et
al
hydrophob
signal
sequenc
remov
proteolyt
cleavag
prior
secret
cell
tabl
boehm
et
al
recent
novel
class
type
ilik
human
ifn
name
identifi
dumouti
et
al
sheppard
et
al
three
gene
cluster
human
chromosom
compris
exon
sever
intron
tabl
encod
secret
monomer
protein
amino
acid
type
iii
ifn
also
identifi
speci
mice
bird
fish
product
type
iii
ifn
essenti
compon
innat
immun
respons
first
line
defens
invad
pathogen
gale
foy
ifn
exert
autoand
paracrin
action
within
hour
respons
viral
infect
protect
function
dual
induc
antivir
cellular
state
facilit
clearanc
infect
cell
activ
apoptosi
synergi
proapoptot
agent
tumor
necrosi
factor
tnf
famili
member
depend
intracellular
level
doublestrand
ds
rna
clemen
cell
type
recogn
incom
rna
dna
virus
owe
presenc
intracellular
rna
triphosph
end
ie
lack
cap
structur
dsrna
structur
gener
viral
rna
replic
inde
dsrna
replic
intermedi
essenti
synthesi
new
rna
genom
wherea
dna
virus
often
overlap
open
read
frame
lie
opposit
orient
gener
mrna
transcript
basepair
form
dsrna
stretch
conserv
molecular
pattern
dsrna
recogn
patternrecognit
receptor
prr
best
known
tolllik
receptor
tlr
retino
acidinduc
gene
like
helicas
receptor
rlr
yoneyama
et
al
tlr
present
cell
surfac
endosom
recogn
variou
microbi
structur
wherea
rlr
express
ubiquit
cytoplasm
recogn
viral
structur
activ
lead
product
type
iii
ifn
product
appear
regul
hcv
rna
bind
retino
acidinduc
gene
tolllik
receptor
result
phosphoryl
activ
tumor
necrosi
factor
receptorassoci
factorassoci
nuclear
factor
activ
bind
kinas
inhibitori
kinas
protein
kinas
dimer
phosphoryl
transloc
cell
nucleu
interact
transcript
partner
bind
cognatedna
posit
regulatori
domain
prd
promot
region
target
gene
includ
result
product
secret
b
activ
transcript
factor
ifnstimul
gene
isg
activ
express
viral
compon
signal
pathway
overlap
pathway
activ
phosphoryl
dimer
heterodimer
allow
bind
cognat
virusrespons
element
vre
promot
region
gene
result
product
variou
subtyp
signal
isg
express
c
type
ifn
signal
type
ifn
bind
receptor
signal
activ
associ
protein
kinas
direct
phosphoryl
assembl
heterodim
trimer
ifnstimul
gene
factor
complex
contain
complex
locat
cell
nucleu
bind
ifnstimul
respons
element
isr
target
gene
direct
isg
express
adapt
gale
foy
gale
foy
ank
et
al
onoguchi
et
al
uze
monneron
type
ifn
product
describ
fig
least
differ
tlr
far
identifi
mammal
uematsu
akria
tlr
type
transmembran
prr
possess
extracellular
domain
contain
leucinerich
repeat
lrr
transmembran
domain
intracellular
signal
domain
known
tir
domain
differ
amino
acid
number
molecular
weight
differ
tlr
princip
relat
differ
number
lrr
extracellular
domain
allow
recogn
differ
ligand
tir
domain
interact
variou
adaptor
molecul
myeloid
differenti
primari
respons
protein
tir
domaincontain
adaptor
induc
trif
trifrel
adaptor
molecul
tram
therebi
activ
intracellular
signal
pathway
cell
type
dendrit
cell
rlr
melanoma
differentiationassoci
gene
appear
play
key
role
respons
viral
infect
kato
et
al
contain
two
tandem
caspas
recruit
domain
card
need
activ
doublestrand
rna
bind
rna
helicas
domain
induc
conform
chang
expos
card
domain
downstream
signal
protein
also
contain
two
card
domain
activ
promot
creagh
oneil
seth
et
al
recent
studi
shown
tripartit
motif
protein
ubiquitin
ligas
catalyz
ubiquitin
crucial
step
cytosol
pathway
elicit
host
antivir
respons
gack
et
al
induct
type
iii
ifn
gene
transcript
princip
control
transcript
factor
fig
inact
state
held
cytosol
member
inhibitori
famili
presenc
incom
virus
kinas
ikk
activ
phosphoryl
subsequ
ubiquitin
degrad
proteasom
free
transloc
nucleu
increas
transcript
target
gene
like
inact
form
cytosol
respons
viral
infect
phosphoryl
two
ikklik
kinas
tnf
receptorassoci
factor
traf
associ
activ
tank
bind
kinas
phosphoryl
lead
dimer
transloc
nucleu
hayden
et
al
seth
et
al
express
low
level
cell
also
activ
phosphoryl
honda
et
al
nuclear
architectur
protein
assembl
complex
nucleu
remodel
chromatin
ifn
gene
promot
result
increas
transcript
initi
bind
receptor
ifn
molecul
sandwich
two
chain
receptor
thu
form
ternari
complex
activ
canon
jakstat
pathway
activ
transduct
element
locat
intracytoplasm
tail
receptor
subunit
fig
similar
transcript
respons
induc
type
type
iii
ifn
confirm
microarray
analysi
jakstat
pathway
gene
express
variou
cell
line
doyl
et
al
dumouti
et
al
figur
show
type
ifn
signal
jakstat
pathway
type
iii
ifn
bind
specif
receptor
trigger
activ
tyrosin
transphosphoryl
activ
kinas
induc
format
ifnstimul
gene
compos
two
element
form
two
cytoplasm
peptid
share
nucleotid
ident
member
irf
famili
renam
protein
singl
polypeptid
appar
molecular
weight
kda
compris
two
domain
conserv
aminotermin
dnabind
domain
carboxytermin
statbind
domain
mostli
cytoplasm
inact
untreat
cell
migrat
nucleu
ifn
treatment
phosphotyrosyl
residu
activ
jak
protein
serv
dock
site
phosphoryl
singl
tyrosin
residu
activ
jak
protein
phosphoryl
induc
releas
ifnar
dimer
domain
heterodim
move
nucleu
form
complex
togeth
fig
interact
directli
ifnstimul
respons
element
isr
dna
sequenc
character
isg
may
contain
one
sever
isr
sequenc
promot
sequenc
stat
protein
shown
activ
type
iii
ifn
involv
ifn
respons
may
restrict
certain
cell
type
takaoka
yanai
receptor
subunit
trigger
activ
tyrosin
phosphoryl
activ
lead
format
multimer
complex
activ
factor
gaf
transduc
signal
target
dna
sequenc
isg
known
activ
site
ga
gaf
homodim
tyrosinephosphoryl
protein
gaf
exist
latent
form
cell
cytoplasm
rapidli
activ
follow
bind
receptor
phosphoryl
tyrosin
residu
activ
gaf
transloc
nucleu
bind
ga
sequenc
induc
isg
transcript
recent
shown
heterodim
also
activ
ga
element
takaoka
yanai
addit
novel
cjundepend
signal
transduct
pathway
induc
type
ii
ifn
identifi
pathway
involv
protein
kinas
jak
includ
extracellular
signalregul
kinas
mitogenactivatedextracellular
signalregul
kinas
pathway
appear
oper
parallel
canon
jakstat
signal
pathway
gough
et
al
antivir
state
induc
differ
type
ifn
mediat
variou
ifninduc
protein
bestknown
antivir
effector
produc
result
ifn
cascad
induct
shown
tabl
includ
oligoadenyl
synthetas
oa
doublestrand
rna
activ
protein
kinas
pkr
myxoviru
mx
protein
addit
effector
includ
rnaspecif
adenosin
deaminas
isg
product
ifnstimul
micro
rna
pedersen
et
al
addit
direct
antivir
properti
describ
earlier
ifn
exhibit
potent
immunomodulatori
properti
contribut
antivir
effect
activ
pestka
et
al
ifn
stimul
effector
function
nk
cell
cytotox
lymphocyt
macrophag
upregul
express
major
histocompat
complex
mhc
class
class
ii
molecul
induc
immunoglobulin
synthesi
b
cell
stimul
prolifer
memori
cell
offer
variou
mode
control
viral
replic
modul
innat
adapt
immun
respons
guidotti
chisari
type
ifn
act
activ
matur
dendrit
cell
lead
mhc
upregul
also
upregul
variou
chemokin
chemokin
receptor
costimulatori
molecul
turn
stimul
cell
respons
modul
lymphocyt
respons
promot
differenti
soli
et
al
major
immunoregulatori
cytokin
involv
regul
nearli
phase
immun
inflammatori
respons
includ
activ
differenti
cell
b
cell
nk
cell
macrophag
express
class
ii
mhc
molecul
immun
cell
princip
regul
especi
monocyt
macrophag
also
increas
transcript
light
chain
mhc
class
molecul
addit
regul
cell
function
modul
neutrophil
function
modul
surfac
express
variou
molecul
includ
integrin
chemokin
receptor
gattoni
et
al
b
differ
form
avail
treatment
chronic
hepat
b
c
includ
administ
dose
megaunit
three
time
week
subcutan
polyethylen
glycol
peg
consist
repeat
unit
ethylen
glycol
form
linear
branch
polym
differ
molecular
mass
pegyl
process
peg
chain
coval
attach
ifn
molecul
pegyl
confer
number
properti
molecul
sustain
blood
level
enhanc
antivir
effect
reduc
advers
reaction
well
longer
halflif
improv
patient
complianc
kozlowski
et
al
two
form
pegyl
approv
food
drug
administr
fda
european
medicin
agenc
emea
ifn
use
treatment
viral
infect
includ
molecul
potent
nonglycosyl
form
activ
compar
buckwold
et
al
deliv
continu
implant
devic
pegyl
form
soon
avail
new
molecul
also
develop
includ
human
genom
scienc
rockvil
maryland
novarti
basel
switzerland
novel
recombin
protein
consist
molecul
attach
human
albumin
moieti
halflif
h
allow
dose
interv
week
balan
et
al
pharmacokinet
studi
monkey
show
approxim
slower
clearanc
longer
halflif
singl
subcutan
inject
osborn
et
al
novel
variant
creat
experiment
mean
dna
shuffl
geneshuffl
techniqu
natur
gene
fragment
reassembl
recombin
process
mimic
evolut
geneshuffl
ifn
variant
may
increas
antivir
antiprolif
activ
chang
et
al
librari
clone
gener
maxygen
redwood
citi
california
roch
two
clone
select
improv
vitro
activ
rel
human
one
pegyl
develop
halt
strong
immun
reaction
ifn
infergen
amgen
thousand
oak
california
synthet
recombin
consensu
molecul
creat
scan
sequenc
sever
natur
ifn
assign
recombin
molecul
frequent
observ
amino
acid
posit
keeff
holling
intrins
antivir
activ
ifn
appear
higher
standard
ifn
blatt
et
al
oze
et
al
futur
consensu
depend
develop
pegyl
otherwis
pharmacolog
modifi
form
multiferon
viragen
plantat
florida
highli
purifi
multisubtyp
natur
human
deriv
human
leukocyt
medusa
r
flamel
technolog
lyon
franc
selfassembl
polyaminoacid
nanoparticl
system
use
protein
carrier
novel
longact
nativ
protein
drug
medusa
medusa
current
earli
clinic
develop
variou
type
oral
administ
also
develop
chronic
hcv
infect
curabl
cure
goal
antivir
therapi
success
treatment
character
sustain
virolog
respons
svr
defin
undetect
hcv
rna
sensit
assay
detect
limit
intern
unit
iu
ml
month
end
therapi
recent
largescal
followup
studi
shown
relaps
recurr
year
patient
svr
swain
et
al
choic
potenti
treatment
chronic
hepat
c
empir
time
caus
agent
chronic
nona
nonb
hepat
yet
identifi
way
evalu
hcv
replic
thu
antivir
activ
drug
first
cohort
patient
chronic
nona
nonb
hepat
treat
signific
declin
alanin
aminotransferas
alt
level
observ
patient
liver
histolog
improv
end
therapi
three
patient
biopsi
ten
year
later
patient
free
infect
lau
et
al
first
nation
institut
health
nih
consensu
develop
confer
manag
hepat
c
held
recommend
standard
use
dose
week
treatment
chronic
hepat
c
howev
svr
rate
still
treatment
schedul
di
biscegli
hoofnagl
lindsay
et
al
develop
pegyl
found
ensur
sustain
drug
exposur
pegyl
administ
fix
dose
wherea
pegyl
administ
weightadjust
dose
pegyl
ifn
report
yield
twofold
higher
svr
rate
correspond
standard
administ
alon
week
ribavirin
guanosin
analogu
broad
spectrum
activ
dna
rna
virus
sidwel
et
al
ribavirin
modestli
transient
inhibit
hcv
replic
vivo
pawlotski
et
al
effici
prevent
relaps
ifnribavirin
combin
therapi
bronowicki
et
al
underli
mechan
unknown
first
trial
standard
ribavirin
combin
therapi
hcv
erad
patient
receiv
combin
none
monotherapi
brillanti
et
al
random
control
trial
mchutchison
et
al
poynard
et
al
led
approv
standard
combin
standard
treatment
chronic
hepat
c
develop
pegyl
ifn
ribavirin
administ
dose
gday
depend
bodi
weight
hcv
genotyp
higher
dose
may
necessari
heavi
patient
addit
ribavirin
increas
svr
rate
respect
compar
standard
monotherapi
mchutchison
et
al
poynard
et
al
three
main
registr
trial
random
control
studi
involv
patient
without
cirrhosi
pegyl
plu
ribavirin
gave
global
svr
rate
compar
pegyl
monotherapi
fri
et
al
hadziyanni
et
al
mann
et
al
svr
rate
rang
patient
hcv
genotyp
infect
patient
hcv
genotyp
infect
littl
inform
avail
patient
genotyp
svr
rate
patient
hcv
genotyp
infect
appear
close
patient
genotyp
infect
pretreat
variabl
correl
sustain
viral
erad
includ
hcv
genotyp
lower
baselin
viral
load
lower
bodi
weight
younger
age
milder
hepat
fibrosi
fri
et
al
hadziyanni
et
al
mann
et
al
pivot
trial
approxim
patient
discontinu
therapi
advers
event
dose
reduct
requir
case
fri
et
al
hadziyanni
et
al
mann
et
al
neutropenia
thrombocytopenia
frequent
associ
administr
hemolyt
anemia
frequent
advers
effect
ribavirin
administr
fri
et
al
hadziyanni
et
al
mann
et
al
ribavirinassoci
anemia
sever
demand
discontinu
dose
reduct
pegyl
combin
therapi
improv
increas
dose
pegyl
andor
ribavirin
select
patient
tailor
length
treatment
virolog
respons
optim
dose
ribavirin
still
uncertain
approv
dose
gday
patient
infect
hcv
genotyp
gday
patient
weight
less
kg
respect
infect
hcv
genotyp
howev
sever
studi
suggest
higher
serum
ribavirin
concentr
associ
higher
svr
rate
jen
et
al
jen
et
al
lindahl
et
al
patient
infect
hcv
genotyp
probabl
svr
increas
auc
ribavirin
concentr
snoeck
et
al
addit
proport
patient
achiev
svr
higher
standard
weightbas
dose
ribavirin
low
dose
although
advers
effect
frequent
seriou
use
high
ribavirin
dose
averag
gday
treat
patient
highviralload
hcv
genotyp
infect
feasibl
lead
svr
patient
lindahl
et
al
use
higher
ribavirin
dose
offset
potenti
increas
drugrel
toxic
princip
hemolyt
anemia
especi
dose
mgkg
epoetin
darbepoetin
epoetin
prodrug
use
reduc
incid
sever
anemia
howev
neither
fda
emea
approv
use
drug
treatment
chronic
hepat
c
costeffect
approach
question
mchutchison
et
al
patient
hcv
genotyp
infect
svr
rate
strongli
influenc
dose
ribavirin
gday
probabl
suffici
maxim
chanc
achiev
svr
fri
et
al
hadziyanni
et
al
mann
et
al
whether
lower
dose
ribavirin
could
suffici
achiev
svr
rate
current
investig
socal
difficulttotreat
patient
popul
hcv
rna
iuml
bodi
weight
kg
rais
dose
pegyl
ribavirin
significantli
increas
svr
rate
fri
et
al
anoth
studi
weightbas
ribavirin
administr
gday
effect
fix
dose
gday
patient
infect
hcv
genotyp
jacobson
et
al
small
number
cirrhot
patient
infect
hcv
genotyp
respond
previou
cours
pegyl
ribavirin
pegyl
everi
day
combin
ribavirin
induc
svr
sever
case
et
al
ongo
trial
assess
frequent
administr
higher
weekli
dose
pegyl
higher
dose
ribavirin
nonrespond
difficulttotreat
patient
patient
receiv
reinforc
therapi
must
care
monitor
toxic
merit
drawback
growth
factor
administr
consid
current
guidelin
state
length
treatment
tailor
hcv
genotyp
pawlotski
patient
infect
hcv
genotyp
treat
week
gday
ribavirin
wherea
patient
infect
hcv
genotyp
treat
week
gday
ribavirin
hadziyanni
et
al
treatment
must
stop
week
genotyp
patient
drop
hcv
rna
level
rapid
virolog
respons
rvr
defin
hcv
rna
level
iuml
week
therapi
sever
recent
report
suggest
patient
rvr
could
qualifi
shorter
treatment
would
improv
adher
reduc
cost
therapi
convers
extend
treatment
durat
beyond
week
may
achiev
svr
patient
infect
hcv
genotyp
slow
virolog
respons
defin
hcv
rna
declin
log
iuml
valu
iuml
week
detail
inform
see
chapter
zeuzem
volum
hcv
infect
rare
diagnos
acut
phase
acut
infect
individu
asymptomat
patient
develop
chronic
infect
howev
warrant
earli
therapi
occup
exposur
known
date
treatment
start
acut
episod
character
alanin
aminotransferas
elev
alway
start
within
week
onset
symptom
optim
treatment
schedul
acut
hepat
c
controversi
pegyl
monotherapi
standard
dose
week
yield
svr
rate
close
symptomat
patient
refer
tertiari
care
center
de
rosa
et
al
jaeckel
et
al
santantonio
et
al
wiegand
et
al
shorter
therapi
may
envisag
calleri
et
al
combin
ribavirin
recommend
first
cours
pegyl
monotherapi
fail
erad
infect
viral
elimin
appear
independ
hcv
genotyp
hcv
rna
level
calleri
et
al
de
rosa
et
al
jaeckel
et
al
sever
studi
test
chronic
hepat
c
achiev
respons
rate
similar
obtain
similar
fewer
advers
effect
barbaro
et
al
castro
et
al
habersetz
et
al
montalto
et
al
villa
et
al
recent
report
japan
suggest
daili
administr
highli
effect
patient
low
moder
hcv
rna
level
horiik
onji
shiratori
et
al
twicedaili
administr
induct
therapi
also
report
effect
nakajima
et
al
unlik
howev
use
routin
clinic
practic
unless
pegyl
otherwis
modifi
specif
clinic
trial
done
intarcia
therapeut
emeryvil
california
report
well
toler
safe
patient
infect
variou
hcv
genotyp
dose
three
time
weekli
week
dosedepend
virolog
biochem
respons
plauth
et
al
dose
daili
induc
hcv
rna
declin
week
twothird
patient
infect
hcv
genotyp
gorbakov
et
al
recent
trial
svr
achiev
patient
receiv
dose
without
ribavirin
respect
novozhenov
et
al
new
trial
deliv
continu
implant
devic
start
soon
potent
activ
hcv
subgenom
replicon
system
dash
et
al
frese
et
al
lanford
et
al
synergist
immunomodulatori
effect
report
howev
pilot
studi
dose
three
time
per
week
show
antivir
efficaci
patient
infect
hcv
genotyp
respond
standard
therapi
relaps
soza
et
al
exhibit
doseand
timedepend
inhibit
hcv
replic
variou
model
independ
type
ii
ifn
receptor
induc
pathway
marcello
et
al
pegyl
form
soon
enter
clinic
evalu
report
induc
dosedepend
antivir
respons
previous
untreat
patient
nonrespond
pegyl
ribavirin
combin
bain
et
al
balan
et
al
result
phase
ii
trial
untreat
genotyp
patient
recent
report
svr
rate
significantli
differ
among
four
group
patient
receiv
either
standard
pegyl
ribavirin
combin
dose
everi
two
week
everi
week
everi
week
endoftreat
respons
administ
everi
week
combin
ribavirin
similarli
frequent
patient
infect
hcv
genotyp
higher
dose
given
everi
week
current
investig
product
soon
enter
phase
iii
clinic
evalu
consensu
use
variou
popul
hcvinfect
patient
publish
result
variabl
consensu
gave
higher
respons
rate
combin
standard
ribavirin
patient
relaps
standard
monotherapi
miglioresi
et
al
patient
standard
combin
fail
svr
rate
approxim
obtain
consensu
bocher
et
al
contrast
svr
achiev
patient
respond
standard
plu
ribavirin
moskovitz
et
al
recent
direct
comparison
consensu
pegyl
show
similar
svr
rate
respect
previous
untreat
patient
infect
hcv
genotyp
sjogren
et
al
nevertheless
clear
evid
consensu
superior
ifn
given
equival
dose
futur
consensu
depend
develop
pegyl
otherwis
pharmacolog
modifi
form
result
therapi
theoret
improv
use
bettertoler
drug
mimic
action
ribavirin
andor
use
hcv
inhibitor
combin
substanti
reduc
hcv
replic
sinc
mechan
action
ribavirin
still
unknown
credibl
altern
approach
current
avail
contrast
mani
specif
inhibitor
hcv
replic
cycl
preclin
develop
sever
reach
clinic
develop
pawlotski
et
al
number
test
combin
pegyl
without
ribavirin
serin
proteinas
inhibitor
telaprevir
vertex
pharmaceut
cambridg
massachusett
boceprevir
sch
scheringplough
corpor
kenilworth
new
jersey
advanc
phase
ii
clinic
trial
recent
trial
hcv
rna
becam
undetect
iuml
patient
receiv
tripl
combin
pegyl
ribavirin
telaprevir
day
preliminari
result
prove
phase
ii
trial
show
week
treatment
telaprevir
plu
pegyl
ribavirin
hcv
rna
undetect
iuml
significantli
genotyp
treatmentna
patient
arm
receiv
dual
combin
pegyl
ribavirin
without
telaprevir
respect
telaprevir
administr
associ
frequent
dermatolog
especi
rash
pruritu
gastrointestin
side
effect
mchutchison
et
al
telaprevir
withdrawn
week
group
patient
continu
pegyl
ribavirin
variou
time
trial
tripl
combin
given
week
dual
combin
pegyl
telaprevir
without
ribavirin
undergo
treatmentna
nonrespond
patient
prove
prove
nonrespond
antivir
effect
boceprevir
appear
strictli
addit
pegyl
sarrazin
et
al
ongo
phase
ii
clinic
trial
higher
dose
boceprevir
administ
treatmentna
patient
combin
pegyl
ribavirin
resist
problem
drug
administ
alon
need
care
monitor
use
combin
ribavirin
inhibitor
rnadepend
rna
polymeras
belong
two
categori
nucleosidenucleotid
inhibitor
target
catalyt
site
enzym
nonnucleosid
inhibitor
target
alloster
site
rdrp
pawlotski
et
al
three
rdrp
inhibitor
test
clinic
trial
includ
two
nucleosid
inhibitor
valopicitabin
idenix
pharmaceut
cambridg
massachusett
novarti
roch
nonnucleosid
inhibitor
viropharma
exton
pennsylvania
wyeth
pharmaceut
madison
new
jersey
pawlotski
et
al
phase
iib
trial
involv
hcv
treatmentrefractori
patient
valopicitabin
dosedepend
addit
effect
pegyl
afdhal
et
al
frequent
gastrointestin
sideeffect
report
develop
valopicitabin
halt
phase
ii
trial
hcv
genotyp
patient
receiv
combin
pegyl
day
hcv
rna
level
fell
pegyl
ifn
alon
log
iuml
combin
group
log
iuml
pegyl
group
viral
breakthrough
due
resist
select
occur
day
administr
villano
et
al
combin
pegyl
ifn
alpha
ribavirin
recent
progress
phase
ii
clinic
develop
studi
need
establish
potenti
benefit
drawback
ad
hcv
replic
cycl
inhibitor
pegyl
combin
current
standard
care
hbvinfect
patient
subdivid
two
group
accord
presenc
absenc
circul
hepat
b
e
hbe
antigen
ag
hbeagneg
patient
produc
hbeag
infect
viru
harbor
precor
andor
core
promot
nucleotid
substitut
carman
et
al
gener
lower
fluctuat
hbv
dna
level
sever
cours
diseas
chronic
hbv
infect
current
curabl
coval
close
circular
dna
cccdna
persist
hepatocyt
nucleu
antivir
treatment
chronic
hepat
b
tripl
aim
slow
progress
fibrosi
cirrhosi
prevent
hepat
failur
prevent
hepatocellular
carcinoma
profound
sustain
inhibit
hbv
replic
necessari
goal
achiev
treatment
consist
shortterm
therapi
gener
longterm
possibl
lifelong
therapi
specif
nucleosidenucleotid
analogu
inhibitor
hbv
replic
virolog
respons
assess
measur
hbv
dna
level
serum
therapi
best
predictor
outcom
antivir
treatment
suggest
hbv
viral
load
reduc
less
iuml
de
franchi
et
al
keeff
et
al
liaw
et
al
lok
mcmahon
ideal
outcom
undetect
hbv
dna
iuml
highli
sensit
realtim
pcrbase
assay
hbeagposit
patient
loss
hbeag
follow
emerg
antihb
antibodi
e
seroconvers
indic
sustain
respons
therapi
persist
treatment
cessat
hb
seroconvers
loss
hbsag
emerg
antihb
antibodi
desir
endpoint
indic
complet
respons
sustain
remiss
hbv
diseas
rare
achiev
current
therapi
first
use
empir
chronic
hepat
b
effect
human
recombin
lymphocyt
prolifer
differenti
studi
patient
chronic
hepat
b
inhibit
immunoglobulin
synthesi
observ
author
postul
immunomodulatori
effect
could
import
therapeut
respons
chronic
hepat
b
first
studi
evalu
antivir
efficaci
involv
nine
patient
receiv
differ
dose
administ
three
time
week
two
week
two
enter
sustain
remiss
undetect
hbv
dna
loss
hbeag
alt
normal
dooley
et
al
two
form
use
treatment
chronic
hepat
b
name
standard
pegyl
standard
use
chronic
hbv
infect
dose
million
unit
mu
daili
mu
three
time
week
de
franchi
et
al
cours
initi
recommend
soon
appear
longer
treatment
month
could
result
frequent
durabl
respons
hui
et
al
lampertico
et
al
lampertico
et
al
metaanalysi
random
control
trial
involv
hbeagposit
patient
show
week
treatment
hbeag
lost
case
hbe
seroconvers
compar
control
arm
wong
et
al
hbeag
relaps
patient
receiv
shortest
treatment
lau
et
al
lok
et
al
niederau
et
al
van
zonneveld
et
al
clearanc
hbsag
seroconvers
antihb
antibodi
rare
occur
late
patient
year
treatment
european
studi
hbsag
lost
sustain
hbe
seroconvert
year
bortolotti
et
al
fattovich
et
al
niederau
et
al
standard
treatment
shown
reduc
risk
cirrhosi
hepatocellular
carcinoma
use
therapi
controversi
hbeagneg
patient
sustain
respons
hbe
seroconvers
expect
four
random
control
trial
show
reduct
hbv
dna
level
end
treatment
patient
compar
untreat
control
fattovich
et
al
lampertico
et
al
manesi
hadziyanni
pastor
et
al
howev
half
virolog
respond
relaps
treatment
discontinu
relaps
continu
occur
year
posttherapi
papatheodoridi
et
al
despit
high
relaps
rate
sustain
virolog
respons
sustain
inhibit
viral
replic
achiev
onethird
patient
year
treatment
kaymakoglu
et
al
longer
ifn
treatment
period
month
associ
higher
rate
sustain
virolog
respons
lampertico
et
al
lampertico
et
al
two
small
studi
repeat
therapi
standard
involv
hbeagposit
hbeagneg
patient
carreno
et
al
manesi
hadziyanni
retreat
nonrespond
responderrelaps
result
sustain
virolog
respons
case
respect
howev
result
difficult
interpret
first
dose
regimen
interv
retreat
variabl
pegyl
pegyl
approv
american
european
author
treatment
chronic
hepat
b
base
two
larg
pivot
trial
involv
hbeagpost
hbeagneg
patient
marcellin
et
al
pegyl
also
test
hbeagposit
hbeagneg
patient
flink
et
al
janssen
et
al
kaymakoglu
et
al
zhao
et
al
clinic
phase
ii
trial
efficaci
variou
dose
pegyl
weekli
administ
week
studi
patient
comparison
standard
dose
mu
three
time
week
cooksley
et
al
end
followup
week
end
therapi
hbeag
lost
patient
receiv
pegyl
weekli
patient
receiv
standard
addit
endpoint
combin
hbeag
loss
hbv
dna
log
copiesml
alt
normal
reach
pegyl
patient
whatev
dose
regimen
compar
patient
receiv
standard
cooksley
et
al
larger
clinic
trial
test
pegyl
monotherapi
weekli
dose
end
followup
hbeag
seroconvers
occur
patient
alt
normal
patient
approv
pegyl
treatment
schedul
hbeagposit
patient
current
weekli
week
possibl
howev
lower
dose
andor
shorter
treatment
may
suffici
zhao
et
al
studi
therefor
need
hui
et
al
pegyl
week
therapi
yield
seroconvers
rate
week
end
treatment
janssen
et
al
sever
recent
studi
suggest
hbv
genotyp
influenc
treatment
outcom
hbv
genotyp
b
infect
tend
respond
better
pegyl
hbv
genotyp
c
infect
flink
et
al
janssen
et
al
zhao
et
al
howev
data
need
use
hbv
genotyp
tailor
treatment
one
larg
trial
evalu
week
treatment
pegyl
hbeagneg
patient
week
followup
patient
normal
alt
level
hbv
dna
level
copiesml
hbsag
lost
case
trial
pegyl
given
week
patient
achiev
hbv
dna
level
copiesml
kaymakoglu
et
al
two
publish
cohort
studi
pegyl
effect
approxim
onethird
hbeagposit
patient
standard
lamivudin
fail
flink
et
al
leeman
et
al
studi
evalu
standard
combin
lamivudin
wherea
recent
trial
test
pegyl
combin
nucleosidenucleotid
analogu
aim
determin
whether
combin
therapi
could
increas
antivir
efficaci
reduc
advers
effect
hinder
emerg
analogueresist
viral
variant
simultan
sequenti
protocol
test
sever
studi
test
lamivudin
standard
given
simultan
week
one
trial
involv
hbeagposit
patient
sustain
hbe
seroconvers
undetect
hbv
dna
pgml
significantli
frequent
end
followup
patient
receiv
combin
patient
treat
lamivudin
alon
respect
barbaro
et
al
contrast
lamivudin
plu
standard
effect
lamivudin
alon
hbeagneg
patient
akarca
et
al
yurdaydin
et
al
incid
lamivudin
resist
nonetheless
lower
coadminist
jang
et
al
santantonio
et
al
conflict
result
report
pegyl
lamivudin
combin
therapi
random
control
trial
involv
hbeagposit
patient
sustain
virolog
respons
hbv
dna
copiesml
hbe
seroconvers
frequent
patient
receiv
pegyl
lamivudin
mg
daili
patient
receiv
lamivudin
monotherapi
chan
et
al
b
contrast
differ
rate
alt
normal
histolog
improv
lamivudin
resist
frequent
lamivudin
monotherapi
combin
therapi
patient
respect
anoth
trial
involv
hbeagposit
patient
favor
pegyl
plu
lamivudin
lamivudin
monotherapi
pegyl
monotherapi
despit
addit
antivir
effect
anoth
studi
involv
hbeagposit
patient
week
treatment
pegyl
yield
hbe
seroconvers
rate
whether
given
alon
combin
lamivudin
janssen
et
al
combin
improv
liver
histolog
statu
van
zonneveld
et
al
induc
less
resist
lamivudin
hbeagneg
patient
lamivudin
combin
pegyl
improv
rate
alt
normal
hbv
dna
suppress
end
followup
compar
pegyl
alon
nevertheless
declin
viral
load
pronounc
lamivudin
resist
less
frequent
combin
kaymakoglu
et
al
marcellin
et
al
one
trial
assess
combin
pegyl
adefovir
dipivoxil
given
week
hbeagposit
hbeagneg
patient
control
arm
liver
cccdna
serum
hbsag
level
fell
strongli
patient
seroconvert
antihb
end
followup
wursthorn
et
al
use
sequenti
combin
therapi
base
notion
lower
hbv
dna
level
nucleosidenucleotid
analogu
therebi
permit
partial
immun
recoveri
might
improv
subsequ
efficaci
pegyl
one
trial
compar
week
lamivudin
monotherapi
follow
week
lamivudinestandard
combin
therapi
week
lamivudin
monotherapi
hbeagposit
patient
sarin
et
al
rate
sustain
virolog
respons
defin
hbe
seroconvers
undetect
hbv
dna
copiesml
week
end
treatment
significantli
higher
combin
lamivudin
monotherapi
recent
studi
hbeagposit
patient
conduct
group
compar
week
lamivudin
monotherapi
follow
week
pegyl
therapi
week
pegyl
monotherapi
sarin
et
al
six
month
end
treatment
hbv
dna
undetect
copiesml
patient
receiv
sequenti
therapi
patient
pegyl
monotherapi
hbeag
loss
also
frequent
sequenti
therapi
group
vs
respect
sarin
et
al
hbeagneg
patient
week
lamivudin
monotherapi
follow
month
pegyl
therapi
includ
month
concomit
administr
compar
week
lamivudin
monotherapi
vassiliadi
et
al
end
followup
rate
alt
normal
significantli
higher
sequenti
therapi
lamivudin
alon
differ
proport
patient
undetect
hbv
dna
observ
similar
result
obtain
chines
cohort
studi
shi
et
al
antivir
efficaci
administ
week
dose
million
unit
daili
studi
small
seri
hbeagposit
patient
hbe
seroconvers
observ
half
patient
alt
normal
four
patient
five
kagawa
et
al
sequenti
therapi
lamivudin
test
hbeagposit
patient
enomoto
et
al
sustain
virolog
respons
achiev
patient
week
end
therapi
pilot
studi
therapi
patient
therapi
fail
hbv
dna
becam
undetect
patient
munoz
et
al
antivir
efficaci
evalu
vitro
human
hepatocytederiv
cell
reduc
hbv
replic
result
suggest
antivir
efficaci
vivo
would
limit
hong
et
al
exhibit
antivir
activ
hbv
vitro
parvez
et
al
addit
found
reduc
hepat
fibrosi
month
compar
untreat
control
weng
et
al
worldwid
million
hbsag
carrier
also
infect
hepat
ddelta
viru
hdv
gaeta
et
al
situat
repres
major
therapeut
challeng
patient
advanc
liver
diseas
includ
cirrhosi
case
hepatocellular
carcinoma
fattovich
et
al
saracco
et
al
specif
hdv
inhibitor
develop
treatment
difficult
hbvhdv
infect
hbv
monoinfect
hdv
rna
level
serum
use
monitor
treatment
efficaci
endpoint
therapi
hdv
rna
clearanc
alt
normal
sometim
achiev
end
treatment
sustain
respons
lead
hbsag
clearanc
serum
date
standard
pegyl
approv
american
european
author
treatment
chronic
hepat
clinic
pilot
trial
conduct
earli
suggest
could
inhibit
hdv
replic
sustain
inhibit
depend
dose
durat
therapi
relaps
frequent
farci
et
al
gaudin
et
al
madejon
et
al
rosina
et
al
complet
respons
character
normal
alt
level
undetect
hdv
rna
observ
six
month
end
treatment
patient
receiv
high
dose
standard
compar
patient
receiv
low
dose
treatment
respect
treatment
shown
provid
clinic
benefit
regress
advanc
hepat
fibrosi
pretreat
characterist
shown
predict
respons
possibl
influenc
hdv
genotyp
respons
known
niro
et
al
sever
strategi
develop
improv
efficaci
standard
treatment
particular
treatment
prolong
year
toler
poor
lau
et
al
three
recent
studi
evalu
efficaci
safeti
pegyl
monotherapi
patient
hbvhdv
infect
castelnau
et
al
erhardt
et
al
niro
et
al
first
test
pegyl
given
week
patient
virolog
respons
defin
undetect
hdv
rna
achiev
patient
alt
normal
frequent
end
followup
end
therapi
castelnau
et
al
second
studi
random
control
trial
evalu
efficaci
week
pegyl
therapi
virolog
respons
achiev
patient
niro
et
al
last
studi
assess
efficaci
safeti
week
pegyl
administr
patient
sustain
virolog
respons
defin
undetect
hdv
rna
alt
normal
occur
patient
differ
rate
sustain
virolog
respons
might
explain
differ
frequenc
cirrhosi
three
studi
popul
drug
ribavirin
may
directli
reduc
hdv
replic
specif
inhibitor
hbv
replic
lamivudin
adefovir
dipivoxil
test
combin
patient
chronic
hepat
ribavirin
inhibit
hdv
replic
hepatocyt
cultur
di
biscegli
howev
ribavirin
monotherapi
effect
patient
chronic
hepat
pilot
studi
evalu
efficaci
ribavirin
mgkg
administ
week
patient
end
followup
hdv
rna
level
reduc
one
patient
alt
level
never
normal
garripoli
et
al
efficaci
standard
mu
three
time
week
combin
ribavirin
mg
daili
evalu
two
studi
last
month
gunsar
et
al
kaymakoglu
et
al
ribavirin
increas
efficaci
anoth
trial
test
efficaci
cours
pegyl
alon
vs
week
pegyl
plu
ribavirin
follow
week
pegyl
alon
virolog
respons
achiev
patient
respect
rate
biochem
respons
similar
niro
et
al
thu
ribavirin
ineffect
chronic
hepat
whether
given
alon
combin
lamivudin
monotherapi
effect
hdv
lau
et
al
niro
et
al
lamivudin
adjunct
slightli
improv
efficaci
standard
canbakan
et
al
wolter
et
al
recent
random
multicent
trial
compar
efficaci
pegyl
monotherapi
adefovir
monotherapi
pegyl
combin
administ
week
patient
chronic
hepat
adefovir
inhibit
hdv
replic
combin
addit
benefit
compar
pegyl
monotherapi
term
hdv
rna
level
yurdaydin
et
al
one
first
drug
test
human
immunodefici
viru
hiv
recombin
human
inhibit
hiv
replic
normal
peripher
blood
mononuclear
cell
ho
et
al
howev
abil
inhibit
hiv
replic
vitro
depend
larg
viral
isol
target
cell
ifn
concentr
inoculum
appear
interfer
assembl
andor
releas
newli
form
virion
ferni
et
al
hansen
et
al
poli
et
al
addit
may
inhibit
viral
protein
synthesi
block
viral
rna
translat
coccia
et
al
may
also
prevent
cell
infect
gendelman
et
al
vivo
suggest
block
de
novo
infect
rather
virion
product
find
support
vitro
studi
show
effect
use
rather
viral
challeng
ifn
therapi
hiv
infect
abandon
advers
effect
modest
inher
antivir
efficaci
develop
highli
activ
antiretrovir
therapi
haart
lane
sever
trial
evalu
antivir
efficaci
standard
hivinfect
patient
also
receiv
zidovudin
comparison
zidovudin
alon
combin
effect
zidovudin
monotherapi
either
adult
fernandezcruz
et
al
fischl
et
al
krown
et
al
infant
giovannini
et
al
prospect
pilot
studi
involv
nine
patient
coinfect
hiv
hcv
genotyp
hiv
replic
show
slow
continu
declin
first
week
pegyl
administr
rebound
pegyl
withdrawn
pegyl
also
report
display
antiretrovir
activ
two
patient
refractori
hivrel
kaposi
sarcoma
van
der
end
et
al
hivinfect
patient
condylomata
acuminata
brockmey
et
al
final
pegyl
shown
particip
earli
control
viral
replic
primari
infect
combin
antiretrovir
drug
emili
et
al
howev
control
group
studi
investig
therefor
need
tabl
illustr
role
type
ifn
human
viral
infect
hodson
et
al
isomura
et
al
kalil
et
al
lewi
amsden
phillpott
et
al
rahal
et
al
sainz
et
al
scagnolari
et
al
solomon
et
al
rahal
et
al
solomon
et
al
conclus
conclus
ifn
proven
invalu
tool
fight
chronic
viral
hepat
indic
antivir
properti
play
major
role
remain
unclear
whether
immunomodulatori
properti
also
import
disappoint
result
obtain
pure
immunomodulatori
molecul
interleukin
tolllik
receptor
agonist
suggest
immunomodul
play
role
potent
inhibit
viral
replic
also
need
role
ifn
treatment
viral
infect
hepat
b
c
remain
elus
